Bayban’s Quest Diagnostics DGX Stock Holding History

Bayban’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12K	Hold	10	–	–	﹤0.01%	530
2026 Q1	$1.96K	Hold	10	–	–	﹤0.01%	567
2025 Q4	$1.74K	Buy	+10	New	+$1.82K	﹤0.01%	551

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Bayban's DGX Position: Q2 2026 in Review

Bayban held its Quest Diagnostics (DGX) position steady in Q2 2026 at 10 shares worth $2.12K. The position accounts for ﹤0.01% of the portfolio, ranked #530.

Bayban first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. 1,046 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Bayban held 10 shares of Quest Diagnostics worth $2.12K as of Q2 2026.
Bayban left its Quest Diagnostics share count unchanged in Q2 2026.
Quest Diagnostics made up ﹤0.01% of Bayban's portfolio in Q2 2026, its #530 holding.
Bayban first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
1,046 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Bayban's 13F filing for Q2 2026, filed 30 Jul 2026.